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Abstract
Blood is scarce and there will never be zero risk. Thus, multidisciplinary approaches to reduce 
or avoid allogeneic blood transfusion in medicine and surgery are discussed.
In medical patients — depending on the situation — causes of anaemia should be investigated, 
nutritional deficiencies corrected and erythropoietic stimulating agents (ESA) used with or 
without intravenous (iv) iron.
In surgical patients, it is important to check the blood count, evaluate the history of bleeding 
and drug therapy far in advance of surgery to allow time for diagnosis, anemia correction, 
haemostasis optimization or decision for a pre-deposit autologous donation.
During intraoperative period bleeding can be minimized through the use of anaesthetic and 
surgical techniques, correcting hypothermia, acidosis, hypocalcaemia or hyperkaliemia. Also 
the use of pharmacological agents such as haemostatic sealants, antifibrinolytics, procoa­
gulants and methods of autologous transfusion (acute normovolemic haemodilution, intracel-
lular cell salvage) helps minimize the dependence on allogeneic blood transfusion. During acute 
bleeding, the use of thromboelastometry gives a full haemostasis overview and allows for more 
targeted use of platelet concentrates and fibrinogen. It has also been shown to reduce intra­
operative transfusion requirements in high-risk surgical patients.
In conclusion, the above-mentioned strategies, when included in protocols and guidelines, can 
substantially contribute to the reduction of the use of allogeneic blood.
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Introduction
Strategies to minimize or avoid allogeneic 
blood transfusion must always be taken into con-
sideration. Blood is scarce, expensive and there 
will never be zero risk. That is why benefits and 
risks must be carefully weighted for each individual 
patient.
Blood remains essential for many bleeding 
surgeries, such as cardiac, liver, trauma or other 
surgical procedures or for patients with malignan-
cies who cannot be given chemotherapy without 
the support of blood components [1]. The use of 
erythropoietic stimulating agents, the management 
of nutritional deficiencies, the administration of 
pharmacological agents to support hemostasis, as 
well as well-defined policies for surgical patients 
may limit the use of allogeneic blood. And for this 
purpose protocols and guidelines are required. 
Reasons for minimization and avoidance 
of the use of allogeneic blood
Although many advances have been made 
in the procedures that help to avoid transfusion-
transmitted infections, zero risk does not exist [2]. 
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There are many factors that need to be considered 
such as donors in the ‘window period’ of infectious 
diseases, not screened agents, emerging agents 
(WNV, malaria, Trypanosoma cruzi), unknown 
viruses, new agents that seem to appear every 
5 years or so, as well as transfusion immune or 
non-immune reactions. Shortage of blood may also 
result from regular donors getting older or from 
donors being unsuitable due to their higher-risk 
life styles (body piercing, tattooing, international 
travel, etc.). Moreover, the cost of blood is rising 
due to the use of new screening technologies, uni-
versal leukocyte reduction, pathogen inactivation 
and irradiation of some blood components. Finally, 
allogeneic blood is forbidden in Jehovah’s Witness 
patients because of their specific interpretation of 
the Scriptures (Table 1).
Transfusion in medical patients
Red blood cell (RBC) transfusions are adminis-
tered to patients to improve oxygen supply to the 
tissues. Rapid increase in hemoglobin (Hb) levels 
is achieved but the benefits are transient. Such 
transfusions are used for symptomatic patients 
and/or those who need rapid improvement of Hb. 
Prophylactic transfusion is not recommended.
The WHO defines anemia as Hb < 13 g/dl 
in ♂ and Hb < 12 g/dl in ♀. Any level of anaemia 
should be investigated and treated for its underlying 
cause (s). The most common anemias are due to 
nutritional deficiencies (iron, vitamin B12, foliates).
Iron deficiency, with or without anaemia symp-
toms, should be treated with iron supplementation 
to correct the anemia and/or replenish the body 
stores [3]. Under normal circumstances oral iron 
is the treatment of choice as it is the most physio-
logical, simple, safe and cheap form but iron can 
also be administered intravenously for several 
other reasons (Table 2) [4, 5] 
On the other hand it should be kept in mind 
that iron is a pro-oxidant and as such it is an im-
portant source of nutrition for many bacteria. It is 
therefore contraindicated during acute infections [6].
Avoiding blood transfusion  
in cancer patients
In ambulatory cancer patients anemia is de-
termined through ordering at first visit of complete 
blood count with reticulocytes, measurement of iron 
parameters [serum iron, total iron-binding capacity, 
transferrin saturation (Tsat), serum ferritin], vitamin 
B12, foliates, creatinine and C-Reactive Protein [7].
Anaemia in cancer patients is multifacto-
rial (Table 3), although the most likely causes 
are anemia of chronic disease (ACD) (Table 4) 
and chemotherapy-induced anaemia (CIA) [7, 8]. 
Anemia of chronic disease is mediated by several 
inflammatory cytokines [7, 9]. IL-6 induces the 
synthesis of Hepcidin, a peptid hormone that regu-
lates the efflux of cellular iron and its distribution 
in the body. It degrades Ferroportin, the main ex-
porter of iron from cells, reducing the accessibility 
of storage iron from reticulo-endothelial system 
(RES), as well as iron export from enterocytes 
to the duodenum. This provokes functional iron 
deficiency (FID) characterized by the presence of 
adequate iron stores but insufficient iron available 
Table 2. Indications for iv iron
— Per os iron intolerance
— Malabsortion (celiac disease, inflammatory bowel 
disease, gastric by-pass)
— Ongoing blood loss (e.g. Osler-Weber-Rendu)
— Severe iron deficiency
— Functional iron deficiency (anaemia of renal failure 
or chronic disease, stimulation of Hb synthesis with 
ESA)
— Autologous blood donation
— Rapid pre-surgery correction
— Increased iron needs (pregnancy*)
*Forbidden during first trimester
Table 1. Reasons to avoid/minimize allogeneic blood
Residual risks of transfusion-transmitted infections
Window period’
Not screened
Unknown
Emergents
Transfusion reactions
Immune
Non-immune
Highcost
Universal leukocyte reduction
Nucleic acid amplification technology
Microbial inactivation procedures
Blood is scarce
Old donors
Process of blood donor selection
Rejection of blood transfusion
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for erythroblast production. The same occurs 
when iron demands are increased by bone marrow 
stimulation like in therapy with erythropoietic 
stimulating agents (ESA) [10].
Erythropoietic stimulating agents
Erythropoietin is a recombinant glycoprotein 
that contains human-identical amino-acid se-
quence and is biologically indistinguishable from 
human erythropoietin. Darbepoietin a activates 
the same receptors as recombinant epoietin, but 
has a two to three times longer half-life due to 
its higher carbohydrate content, which creates 
the potential for prolongation of dosing intervals 
(Figure 1) [11, 12]. 
The commonly used ESAs include Epoietin a 
(40 000 UI), Epoietin b (30 000 UI) given weekly, 
and Darbepoietin given either 150 mcg weekly, or 
300 mcg every two weeks followed by 500 mcg 
every three weeks.
In cancer patients the treatment with ESA of 
symptomatic chemotherapy-induced anaemia is 
aimed at improvement of the quality of life and mini-
mization of transfusion requirements. ESA provides 
a smooth and sustained increase in Hb; it is generally 
well tolerated and easy to administrate [10]. 
Blood transfusion however is required for 
symptomatic patients who need a rapid improve-
ment of Hb, for non-responders to ESA or if Hb 
< 9 g/dl [7]. 
Before ESA administration we need to exclude 
nutritional deficiencies (iron, vit. B12, foliates), 
blood loss and history of cardiovascular or thrombo-
embolic adverse events. It is also advisable to assess 
the iron status by measuring Tsat and ferritin. Since 
iron will be consumed during ESA therapy, periodic 
monitoring of iron parameters must be performed 
[10]. Intravenous iron supplementation is re-
quired for patients with FID (ferritin £ 800 ng/ml, 
Tsat < 20%) or absolute iron deficiency (ferritin 
< 30 ng/ml, Tsat < 15%) [7]. 
Iron supplementation improves ESA response 
in the iron-replete patients. The increment in 
hemoglobin level is more effective and rapid for 
patients supplemented with intravenous iron which 
allows for lower ESA dosage [11, 13]. In ACD pa-
tients oral iron is poorly absorbed, so intravenous 
iron administration is the treatment of choice.
If the hemoglobin level approaches or exceeds 
11g/dl, reduction or interruption of the ESA dosage 
should be considered [11]. ESA should be discon-
tinued following the completion of chemotherapy.
Table 3. Causes of anaemia in cancer patients
Anaemia of chronic disease (ACD)
Myelotoxicity from chemotherapy
Haemolysis
Nutritional deficiencies
Blood loss
Bone marrow infiltration
Figure 1. Epoietin vs. darbepoietin structure
Table 4. Physiopathology of anaemia of chronic disease
Iron absorption/movement restricted in gut and RES
Decrease RBC survival
Inadequate erythropoietin response
Inhibition of differentiation/proliferation of erythroid 
progenitor cells
Inhibition of erythropoietin production
Decreased erythropoietin levels
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However, it must be noted that approximately 
1/3 of patients under ESA treatment are non- 
-responders. ESA should be discontinued if no 1 g/dl 
increment of Hb level is reported after 4 weeks of 
treatment or there is no response over a 12-week 
escalation period. Such move is indicated to avoid 
unnecessary long-term therapy or occurrence of 
adverse events [7, 10]. 
Treatment guidelines
1. ESA is administered in the management of 
chemotherapy-induced-anaemia but not ana-
emia caused by cancer.
2. Prophylactic ESA administration is not re-
commended.
3. At Hb £ 9 g/dl transfusion should be conside-
red prior to ESA treatment.
4. Erythropoietin therapy should be initiated 
when the patient is symptomatic with Hb level 
9–10 g/dl.
5. Hb level of £ 12 g/dl should be the target 
otherwise there is the risk of thromboembolic 
events or tumor growth.
6. Individualized treatment should be continued 
for as long as the patient is on chemotherapy 
and symptomatic improvement is reported.
Transfusion in surgical patients
Preoperative period
Preoperative planning is essential for reduc-
tion or avoidance of allogeneic blood transfusions. 
The strategies to avoid allogeneic blood transfu-
sion in surgical patients include correction of 
pre-existing anaemia, identification and control of 
coagulation disorders, use of methods for reduction 
of blood loss and autologous transfusion [14]. They 
usually involve:
 — diagnosis and treatment of nutritional deficien-
cies (iron, vitamin B12, foliates); optimization 
of haemostasis;
 — erythropoietin and/or intravenous iron ad-
ministration;
 — predeposit autologous donation (PAD).
Three to four weeks before surgery, personal 
and/or family history of bleeding and anaemia 
should be evaluated [14]. It is recommended to 
undertake drug therapy including antithrombotic 
medication and to make decisions for discontinu-
ation (if safe) or, substitution of agents that could 
affect clotting during surgery [5, 16, 17]. 
The following tests need to be performed to 
identify and timely treat any type of anaemia or 
bleeding disorder: full blood count, prothrombin 
time (PT) and activated partial thromboplastin 
time (APTT) [16].
Patients with inherited platelet disorders 
(Bernard-Soulier disease, Fanconi anaemia, Glanz-
mann’s thrombasthenia), or coagulation factor 
deficiencies (von Willebrand disease, factor II, 
V, VII, VIII, IX, XI, XII, XIII deficiencies) should 
be followed in specialized centers and prepared 
with deficiency factor replacement before, during 
and after surgery [5, 13]. If the level of anaemia 
is severe and surgery cannot be postponed, the 
use of ESA and/or intravenous iron supplemen-
tation may be considered to increase red cell 
mass. This is particularly true for patients with 
anaemia caused by either renal failure or chronic 
disease [5]. Also its use can be an option before 
predeposit autologous donation (PAD) in anaemic 
patients.
Predeposit autologous donation means col-
lection of the patient’s own blood for reinfusion. 
The use of PAD is considered for surgical patients 
where blood loss is expected. PAD is collected and 
stored during the weeks prior to elective surgery. 
PAD reduces the risk of transfusion-transmitted 
infections, alloimmunization or graft-versus-host 
disease. It also provides compatible blood for 
patients with complex red cell antibodies or an-
tibodies to common red cell antigens. It does not 
however eliminate the risk of bacterial contamina-
tion, ABO mismatch due to clerical errors, some 
febrile reactions or fluid overload [18]. 
Intraoperative period
The combination of several intraoperative 
strategies enables the performance of major sur-
gery procedures with no need for the use of alloge-
neic blood components. The following factors may 
la rgely contribute to the improvement of hemostasis 
during surgery: 
 — choice of anaesthetic and surgical techniques 
to reduce bleeding;
 — patient positioning/hypotention;
 — correction of hypothermia, acidosis, hypocal-
cemia, hyperkalemia;
 — restrictive vs. liberal transfusion (Hb < 7 g/dl 
vs Hb < 9 g/dl);
 — thromboelastometry;
 — pharmacological agents: haemostatic sealants, 
antifibrinolytics (tranexamicacid, e-amino-
caproicacid), procoagulants [1-deamino-8-D-
-arginine vasopressin (DDAVP), fibrinogen, 
prothrombin complex concentrate, rFVIIa];
 — autologous transfusion (intraoperative cell 
salvage, acute normovolemic haemodilution).
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Anesthesia choices and positioning for surgery 
can influence surgical blood loss. Hypothermia 
(temp. < 35°C) is thought to inhibit blood coagu-
lation and impair platelet functions [19]. It is also 
important to maintain PH > 7.2, Ca++ serum 
concentration > 1 mmol/l. 
Research studies have also demonstrated that 
restrictive strategy for red blood cell transfusion is 
at least as effective as a liberal transfusion strategy 
in critically ill patients [20]. 
Thromboelastometry (Rotem® System)  
(Figure 2)
Coagulation tests (TP, APTT) and platelet 
count are of limited help in severe bleeding, as they 
neither provide enough information in terms of clot 
formation nor contribute to recognition of fibrinoly-
sis. It also takes too long to obtain the results. 
Thromboelastometry is a point-of-care coagulation 
(POC) method for hemostasis testing in whole 
blood. It permits rapid assessment of the three as - 
pects of coagulation: clot strength, thrombin genera- 
 tion and clot stability as well as a goal-directed 
coagulation management in emergency situations. 
It is the gold standard for diagnosis of premature 
dissolution of the clot (hyperfibrinolysis). Since the 
method of thromboelasometry was introduced for 
hemostasis testing a substantial reduction in RBC 
has been reported and the method serves as a guide 
to intraoperative transfusion in cardiac, vascular 
and other bleeding surgeries (Table 5) [16, 21].
Pharmacologic haemostatic agents should be 
used when bleeding is wide spread and generalized 
or when the bleeding site is not accessible. Topi-
cal sealants can be used depending on the site and 
amount of bleeding [20, 22]. 
The use of rFVIIa in surgical bleeding, although 
off label, may be effective in bleeding patients who 
are unresponsive to standard therapy, i.e. with fresh 
frozen plasma, platelets, fibrinogen [23]. 
Intraoperative cell salvage refers to the collec-
tion and reinfusion of red cells that were lost during 
surgery. This procedure is performed by machines 
commonly known as a “cell savers”, which suction, 
wash the red cells by centrifugation and resuspend 
them in saline so that blood can be given back to the 
patient’s body instead of being thrown away. Intra-
operative cell salvage is used when the expected 
blood loss is large (> 1,5 L) and it is worth noting 
that the procedure is acceptable also by patients 
with religious objections to receiving blood such 
as Jehovah’s Witnesses provided that the collected 
blood remains in continuity with the patient via 
tubing connected to the patient’s intravenous can-
nula and hence, the patient’s circulatory system. 
Contraindications are the possible aspiration of 
malignant cells, or the presence of infection, ascitic 
or amniotic fluids and topical clotting agents [18]. 
Acute normovolemic haemodilution (ANH) is 
a method of autologous transfusion that consists in 
removal of the whole blood before or during induc-
tion of anaesthesia, and simultaneous replacement 
with crystalloid or colloid. If necessary, the blood 
that was removed is returned to the patient. The 
major benefit is the reduction of RBC cell losses 
when whole blood is shed perioperatively at lower 
hematocrit levels after ANH procedure is per-
formed. The drop in red cells mass contributes to 
the decrease in blood viscosity and improvement 
in tissue perfusion. This method should only be 
considered when the estimated blood loss exceeds 
20% of blood volume and the patient does not have 
a severe myocardial disease [18]. 
Figure 2. Rotem® Delta
Table 5. Thromboelastometry characteristics
Uses small quantity of citrated whole blood
Gives full haemostasis overview in 10–15 minutes
Gives clot firmness
Provides more targeted use of platelet concentrates and 
fibrinogen
Permits diagnosis or exclusion of hyperfibrinolysis
Predicts status of coagulation after protamin
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Postoperative period
Anaemia is common after surgery and is 
associated with worse outcomes. Strategies to 
limit the development of anaemia must therefore 
be adopted. Examples of such strategies are: 
 — postoperative cell salvage;
 — ESA and/or iv iron.
In the postoperative cell salvage procedure, 
blood is collected from surgical drains, and then 
reinfused through a special device. The blood is 
diluted, partially haemolysed and defibrinated and 
may contain high levels of cytokines [18]. We have 
no experience with this procedure at Santa Maria 
Hospital in Lisbon.
Administration of ESA and/or iv iron in the 
post-operative period contributes to the improve-
ment of Hb levels. Increase of inhaled oxygen 
content, maintenance of adequate intravascular 
volume and optimization of cardiac performance 
augments oxygen delivery. Furthermore, control 
of fever or shivering and provision of substantial 
bed rest, may reduce oxygen consumption during 
the post-operative period.
Conclusions
It is strongly recommended to adopt strategies 
which help limit blood loss as well as to develop 
alternatives to allogeneic blood use in medical and 
surgical patients. Protocols to guide transfusion 
decisions are equally important for minimalization 
of allogeneic blood use. Conventional practices 
should be based on the needs and expected benefits 
for individual patients. If all these strategies are 
adopted, no elective surgeries need to be cancelled 
for lack of blood and treatment of patients under 
chemotherapy can proceed with no interruption 
even if blood shortage occurs.
References
 1.  Franklin I.M. Introduction. In: Practical Transfusion Medicine 
(2nd ed.). Edited by Michael F. Murphy and Derwood H. Pamphi-
lon. Blackwell Publishing, 2006; 3–12.
 2.  Reeder G.D., Waters J.H. Intraoperative blood recovery. In: 
Blood management options for better patient care. Edited by 
Jonathan H. Waters. AABB Press, 2008; 207–240.
 3.  Goddard A.F., James M.W., McIntyre A.S., Scott B.B. Guidelines 
for the management of iron deficiency anaemia. Gut 2011; 60: 
1309–1316.
 4.  Beris P. The use of iron to increase red cell mass. J. Anesth. 
2003; 50: S3–S9.
 5.  Goodnough L.T., Szpisjak D.F. Preoperative optimization. In: 
Blood management options for better patient care. Edited by 
Jonathan H. Waters. AABB Press, 2008; 159–189.
 6.  Auerbach M., Ballard H. Clinical use of intravenous iron: 
administration, efficacy and safety. Hematology 2010; 2010: 
338–334.
 7.  Henry D.H. Parenteral iron therapy in cancer-associated anemia. 
Hematology 2010; 2010: 351–356.
 8.  Koury M.J., Rhodes M. How to approach chronic anemia. Hema-
tology 2012; 2012: 183–190.
 9.  Weiss G., Goodnough L.T. Anemia of chronic disease. N. Engl. 
J. Med. 2005; 352: 1011–1023.
 10.  Hedenus M., Birgegård G. The role of iron supplementation 
during epoetin treatment for cancer-related anemia. Med. Oncol. 
2009; 26: 105–115.
 11.  Ford P.A. Blood management strategies to treat anemia and 
thrombocythopenia in cancer patients. In: Blood management 
options for better patient care. Edited by Jonathan H. Waters. 
AABB Press, 2008; 119–136.
 12.  Elliot S., Pham E., Macdougall I.C. Erythropoietins: a com-
mon mechanism of action. Experimental Hematology 2008; 36: 
1573–1584.
 13.  Spence R.K. Transfusion therapy in surgery. In: Transfusion 
therapy: clinical principles and practice (3rd ed.). Edited by Paul 
D. Mintz. AABB Press, 2011; 265–303.
 14.  McClelland B., Walsh T. The effective and safe use of blood 
components. In: Practical transfusion medicine (2nd ed.). Edited 
by Michael F. Murphy and Derwood H. Pamphilon. Blackwell 
Publishing, 2006; 67–85.
 15.  Goodnough L.T. Preoperative management and preparation for 
transfusion-free surgery. In: Transfusion-free medicine and surgery. 
Edited by Nicolas Jabbour. Blackwell Publishing, 2007; 60–74.
 16.  Hunt B.J. Bleeding associated with trauma and surgery. In: Prac-
tical transfusion medicine (2nd ed.). Edited by Michael F. Murphy 
and Derwood H. Pamphilon. Blackwell Publishing, 2006; 86–96.
 17.  Spence R.K., Jeter E.K., Mintz P. Transfusion in surgery and trau-
ma. In: Transfusion therapy: clinical principles and practice. Edited 
by Paul Mintz. AABB Press Editorial Board, 1999; 171–197.
 18.  Dafydd T. Autologous transfusion. In: Practical transfusion medi-
cine (2nd ed.). Edited by Michael F. Murphy and Derwood H. 
Pamphilon. Blackwell Publishing, 2006; 298–308.
 19.  Nuttall G.A., Oliver W.C. Ancillary techniques. In: Blood man-
agement options for better patient care. Edited by Jonathan H. 
Waters. AABB Press, 2008; 281–299.
 20.  Shander A., Rijhwani T., Dyga R., Waters J. Postoperative blood 
management strategies. In: Blood management options for bet-
ter patient care. Edited by Jonathan H. Waters. AABB Press, 
2008; 331–354.
 21.  Nuttall G.A., Santrach P. Point-of-care testing. In: Blood mana-
gement options for better patient care. Edited by Jonathan H. 
Waters. AABB Press, 2008; 301–329.
 22.  Cheng D.H., Craig A., Ralley F.E. Special surgical management: 
cardiac surgery. In: Blood management options for better patient 
care. Edited by Jonathan H. Waters. AABB Press, 2008; 423–441.
 23.  Tobias J.D. Intraoperative strategies for transfusion-free surgery. 
In: Transfusion-free medicine and surgery. Edited by Nicolas Jab-
bour. Blackwell Publishing, 2007; 75–113.
